Literature DB >> 22722685

Enzymatic treatment of whey proteins in cow's milk results in differential inhibition of IgE-mediated mast cell activation compared to T-cell activation.

Karen Knipping1, Betty C A M van Esch, Adrie G van Ieperen-van Dijk, Els van Hoffen, Ton van Baalen, Léon M J Knippels, Sicco van der Heide, Anthony E J Dubois, Johan Garssen, Edward F Knol.   

Abstract

BACKGROUND: Cow's milk (CM) hydrolysates are frequently used as milk substitutes for children with CM allergy. In hydrolysates, allergenic epitopes within CM proteins are diminished by enzymatic treatment. The aim of this study was to examine the allergenic and immunogenic properties of whey proteins during hydrolysis.
METHODS: During hydrolysis, samples were obtained at 0, 10, 15, 30, 45, 60, 75 and 90 min. Degradation was checked by HPLC and SDS-PAGE. Allergenic potential was analyzed by IgE crosslinking capacity of human Fcε receptor type 1-transduced rat basophilic leukemia cells sensitized with serum of CM-allergic patients. Whey-sensitized C3H/HeOuJ mice were ear challenged intracutaneously with the hydrolysates. Immunogenicity was tested using whey-specific human T-cell clones and T-cell lines at the level of proliferation and release of IL-4, IL-10, IL-13 and IFN-γ.
RESULTS: After 15 min of hydrolysis, the majority of the proteins were degraded. Hydrolysis for 15 min resulted in 92% inhibition of mast cell degranulation and in 82% reduction of ear swelling in the mouse model. In contrast, T-cell-stimulatory capacity was less affected by hydrolysis: reduction of human T-cell proliferation was only 9%. This was further reduced to 57 and 74% after 30 and 45 min of hydrolysis, respectively. Cytokine production followed the pattern of T-cell proliferation.
CONCLUSION: Via differential analysis of allergenic versus immunogenic properties of the time kinetics of hydrolysis of whey proteins, we have demonstrated specific hydrolysis conditions with reduced IgE-crosslinking responses but retained T-cell activating properties. This approach might be useful in better defining CM hydrolysates.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22722685     DOI: 10.1159/000338007

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  4 in total

1.  Remaining symptoms in half the children treated for milk allergy.

Authors:  Nicole C M Petrus; Anne-Fleur A Schoemaker; Meike W van Hoek; Laura Jansen; Marijke C Jansen-van der Weide; Wim M C van Aalderen; Aline B Sprikkelman
Journal:  Eur J Pediatr       Date:  2014-11-22       Impact factor: 3.183

2.  Development of β-lactoglobulin-specific chimeric human IgEκ monoclonal antibodies for in vitro safety assessment of whey hydrolysates.

Authors:  Karen Knipping; Peter J Simons; Laura S Buelens-Sleumer; Linda Cox; Marcel den Hartog; Niels de Jong; Reiko Teshima; Johan Garssen; Louis Boon; Léon M J Knippels
Journal:  PLoS One       Date:  2014-08-25       Impact factor: 3.240

3.  An In Vitro and In Vivo Translational Research Approach for the Assessment of Sensitization Capacity and Residual Allergenicity of an Extensive Whey Hydrolysate for Cow's Milk-Allergic Infants.

Authors:  Karen Knipping; Laura Buelens; Peter J Simons; Johan Garssen
Journal:  Foods       Date:  2022-07-07

Review 4.  Management of Cow's Milk Allergy from an Immunological Perspective: What Are the Options?

Authors:  Edward F Knol; Nicolette W de Jong; Laurien H Ulfman; Machteld M Tiemessen
Journal:  Nutrients       Date:  2019-11-11       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.